TipRanks
Go Ultimate55% OFF

Eurobio-Scientific SA (E8TN) AI Stock Analysis

DE:E8TN

Eurobio-Scientific SA

(Frankfurt:E8TN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Conservative LeverageDebt-to-equity of about 0.09 and a sizable equity buffer indicate conservative financing. This reduces balance-sheet strain and preserves flexibility to fund product development, distribution expansion, or working-capital needs through the next several quarters.
Negative Factors
Lower Margin DurabilityNet margin of about 2.9% in 2025, versus exceptionally high levels in 2021–2022, shows earnings power has reset lower. Even with gross margin around 40–46%, thinner operating profitability leaves less room to absorb execution pressure or reinvest.

Eurobio-Scientific SA (E8TN) vs. iShares MSCI Germany ETF (EWG)

-25%-20%-15%-10%-5%0%5%10%15%DE:E8TN+8.14%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 258.39M
Dividend Yield
―
Average Volume (3M)
781
Price to Earnings (P/E)
37.6
Beta (1Y)
0.15
Revenue Growth
6.28%
EPS Growth
204.56%
Country
Germany
Employees
443
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Eurobio-Scientific SA Business Overview & Revenue Model

Company Description

Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The...

Eurobio-Scientific SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:E8TN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:ALIKOFR:ALIKO46NeutralEUR 22.42M-5.20-22.03%―37.28%7.83%
FR:ALNOVFR:ALNOV45NeutralEUR 31.94M-0.77-159.70%―10.36%29.41%
FR:ALMDTFR:ALMDT43NeutralEUR 180.85M-3.00271.64%―2.16%-5.26%
FR:ALMKTFR:ALMKT41NeutralEUR 18.94M1.53-157.72%―3.38%―

* Healthcare Sector Average

Performance Comparison

0%50%100%DE:E8TNFR:ALMKTFR:ALNOVFR:ALDMSFR:ALIKOFR:ALMDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:E8TN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:E8TNEurobio-Scientific SA25.901.857.69%
FR:ALMKTMAUNA KEA TECHNOLOGIES0.10-0.00-1.02%
FR:ALNOVNovacyt S.A.0.44-0.02-4.35%
FR:ALDMSDiagnostic Medical Systems0.91-0.41-30.95%
FR:ALIKOIkonisys SA1.42-0.04-2.74%
FR:ALMDTMedian Technologies3.690.7927.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.